NCT06935864

Brief Summary

The current study is to assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors, and its role in the disease progression.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2024

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 16, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 5, 2025

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 20, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2026

Completed
Last Updated

April 20, 2025

Status Verified

April 1, 2025

Enrollment Period

1.3 years

First QC Date

January 5, 2025

Last Update Submit

April 12, 2025

Conditions

Keywords

Bone TumorOsteosarcomaEwing sarcoma

Outcome Measures

Primary Outcomes (1)

  • The prognostic value

    Assess the prognostic value of Krüppel-like factors 4 and 7 in bone tumors,

    1 year

Study Arms (1)

Prospective Arm

Children, young adolescents younger than 15 years, and young adults (15 to 39 years) with histologically confirmed patients with skeletal or extra-skeletal OS or ES with localized or metastatic disease stages.

Diagnostic Test: KLF factor (4 and 7)

Interventions

KLF factor (4 and 7)DIAGNOSTIC_TEST

Immunohistochemical staining of 4 um sections prepared from paraffin blocks using KLF factor (4 and 7) by automated immunostaining using the streptavidin-biotin technique.

Prospective Arm

Eligibility Criteria

Age1 Month - 39 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Children, adolescents, and young adults diagnosed with localized and metastatic both skeletal and extra-skeletal osteosarcoma and Ewing's sarcoma

You may qualify if:

  • Age: children, young adolescents younger than 15 years, and young adults (15 to 39 years) Gender: Males and female. Histologically confirmed patients with skeletal or extra-skeletal OS or ES. Both localized and metastatic disease stages.

You may not qualify if:

  • Patients with second malignant bone sarcoma. Patients with benign bone tumors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ain Shams University

Cairo, 11566, Egypt

RECRUITING

Faculty of Medicine Ain Shams Research Institute- Clinical Research Center (MASRI-CRC)

Cairo, 11566, Egypt

RECRUITING

Related Links

MeSH Terms

Conditions

Bone NeoplasmsOsteosarcomaSarcoma, Ewing

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBone DiseasesMusculoskeletal DiseasesNeoplasms, Bone TissueNeoplasms, Connective TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeSarcoma

Study Officials

  • Fatma S E Ebeid

    Faculty of Medicine Ain Shams University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fatma S E Ebeid, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2025

First Posted

April 20, 2025

Study Start

August 16, 2024

Primary Completion

December 1, 2025

Study Completion

February 1, 2026

Last Updated

April 20, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations